Bioverativ, a Sanofi company

Quick facts

Phase 3 pipeline

• BIVV009 · Hematology
  BIVV009 is a monoclonal antibody that inhibits tissue factor pathway inhibitor (TFPI) to enhance thrombin generation and restore hemostasis in hemophilia patients.
• sutimlimab (BIVV009)

Phase 1 pipeline

• BIV009
• BIVV009 6.5 grams
• BIVV009 7.5 grams
• BIVV020

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Bioverativ, a Sanofi company portfolio CI brief
• Bioverativ, a Sanofi company pipeline updates RSS